Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers.
Journal
HemaSphere
ISSN: 2572-9241
Titre abrégé: Hemasphere
Pays: United States
ID NLM: 101740619
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
03
05
2021
accepted:
12
07
2021
entrez:
23
8
2021
pubmed:
24
8
2021
medline:
24
8
2021
Statut:
epublish
Résumé
Definition of therapy-related myeloid neoplasms (TRMN) is only based on clinical history of exposure to leukemogenic therapy. No specific molecular classification combining therapy-related acute myeloid leukemia and therapy-related myelodysplastic syndromes has been proposed. We aimed to describe the molecular landscape of TRMN at diagnosis, among 77 patients with previous gynecologic and breast cancer with a dedicated next-generation sequencing panel covering 74 genes. We investigated the impact of clonal hematopoiesis of indeterminate potential-associated mutations (CHIP-AMs defined as presence at TRMN stage of mutations described in CHIP with a frequency >1%) on overall survival (OS) and the clinical relevance of a modified genetic ontogeny-based classifier that categorized patients in 3 subgroups. The most frequently mutated genes were
Identifiants
pubmed: 34423258
doi: 10.1097/HS9.0000000000000632
pmc: PMC8373540
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e632Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Références
N Engl J Med. 2005 Apr 14;352(15):1529-38
pubmed: 15829534
Leukemia. 2019 Dec;33(12):2842-2853
pubmed: 31089247
Haematologica. 2020 Mar;105(3):e98-e101
pubmed: 31413096
Gynecol Oncol. 2018 Nov;151(2):190-195
pubmed: 30268525
Nat Genet. 2020 Nov;52(11):1219-1226
pubmed: 33106634
J Clin Oncol. 2018 Sep 10;36(26):2684-2692
pubmed: 30024784
Nature. 2015 Feb 26;518(7540):552-555
pubmed: 25487151
Nat Rev Cancer. 2017 Aug 24;17(9):513-527
pubmed: 28835720
Cell Stem Cell. 2018 Feb 1;22(2):157-170
pubmed: 29395053
Cell Stem Cell. 2018 Nov 1;23(5):700-713.e6
pubmed: 30388424
J Hematol Oncol. 2015 May 08;8:45
pubmed: 25952993
Blood. 2009 May 21;113(21):5090-3
pubmed: 19289855
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
N Engl J Med. 2014 Dec 25;371(26):2477-87
pubmed: 25426838
Cell Stem Cell. 2017 Sep 7;21(3):374-382.e4
pubmed: 28803919
Blood. 2015 Feb 26;125(9):1367-76
pubmed: 25550361
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):24-32
pubmed: 27913458
N Engl J Med. 2017 Feb 9;376(6):536-547
pubmed: 28177873
J Clin Oncol. 2021 May 10;39(14):1584-1594
pubmed: 33449813
Cancer. 2015 Jul 15;121(14):2393-9
pubmed: 25845577
J Clin Oncol. 2021 May 10;39(14):1575-1583
pubmed: 33600210
JAMA Netw Open. 2019 Jan 4;2(1):e187147
pubmed: 30657534
Haematologica. 2013 Jun;98(6):908-12
pubmed: 23349305
Blood. 2003 Jul 1;102(1):43-52
pubmed: 12623843
Rev Med Interne. 2019 Oct;40(10):684-692
pubmed: 31126662
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Blood Adv. 2021 Jan 12;5(1):176-184
pubmed: 33570629
Leuk Res. 2015 Mar;39(3):348-54
pubmed: 25573287
Lancet Oncol. 2017 Jan;18(1):100-111
pubmed: 27923552
JAMA Oncol. 2019 Mar 1;5(3):318-325
pubmed: 30570657
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Ann Oncol. 2021 Aug;32(8):1046-1048
pubmed: 34107346
Lancet Oncol. 2017 Jan;18(1):112-121
pubmed: 27927582
Nature. 2018 Jul;559(7714):400-404
pubmed: 29988082
Nat Med. 2018 Jul;24(7):1015-1023
pubmed: 29988143
Blood. 1997 Mar 15;89(6):2079-88
pubmed: 9058730